TNF-Alpha Inhibitors and Ustekinumab for the Treatment of Psoriasis: Therapeutic Utility in the Era of IL-17 and IL-23 Inhibitors

Psoriasis is a chronic inflammatory condition for which eleven FDA-approved biologic therapies are approved. Over the past decade, studies have documented the higher efficacy of IL-17 and IL-23 inhibitors for the treatment of psoriasis compared to the TNF-alpha inhibitors and ustekinumab, an IL-12/2...

Full description

Saved in:
Bibliographic Details
Published inJournal of Psoriasis and Psoriatic Arthritis Vol. 7; no. 2; pp. 79 - 92
Main Authors Hong, Julie J., Hadeler, Edward K., Mosca, Megan L., Brownstone, Nicholas D., Bhutani, Tina, Liao, Wilson J.
Format Book Review Journal Article
LanguageEnglish
Published Los Angeles, CA SAGE Publications 01.04.2022
Subjects
certolizumab pegol
ustekinumab
comorbidities
etanercept
infliximab
safety profile
TNF-alpha inhibitors
adalimumab
Online AccessGet full text

Cover

More Information
Summary:Psoriasis is a chronic inflammatory condition for which eleven FDA-approved biologic therapies are approved. Over the past decade, studies have documented the higher efficacy of IL-17 and IL-23 inhibitors for the treatment of psoriasis compared to the TNF-alpha inhibitors and ustekinumab, an IL-12/23 inhibitor. Despite this, there remains an important role for the use of TNF-alpha inhibitors and ustekinumab in the treatment of psoriasis. Here, we review how considerations of infection and malignancy risk, patient demographics, treatment resistance, and comorbidities may make certain TNF-alpha inhibitors or ustekinumab an excellent choice for therapy in particular patient subgroups.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2475-5303
2475-5311
DOI:10.1177/24755303211047479